Synta Pharma Home



Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet

Investor Overview

Synta Highlights

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All clinical candidates were invented internally by Synta scientists using our compound library and discove... More >>

Recent NewsMore >>
DateTitle 
05/17/12Synta Announces Presentations at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--May. 17, 2012-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled presentations at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting June 1-5 at the McCormick Place in Chicago. GALAXY – Trial design “The GALAXY Trial™ (NCT01348126): A Randomized 2b/3 Study of Ganetespib (STA-9090) in Combination with Docetaxel versus Docetaxel Alone in Subjects wit... 
Printer Friendly Version
05/03/12Synta to Present at the Deutsche Bank 37th Annual Health Care Conference
Company to Webcast Presentation on May 7 LEXINGTON, Mass.--(BUSINESS WIRE)--May. 3, 2012-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will be presenting at the Deutsche Bank 37th Annual Health Care Conference on Monday, May 7 at 8:40 am (ET) in Boston. A live audio webcast and replay of the panel will be available on the "Investors" section of the Company's website, www.syntapharma.com. ... 
Printer Friendly Version
05/03/12Synta Provides Clinical Update and Reports First Quarter 2012 Financial Results
-Company announces plans to proceed into Phase 3 stage of the GALAXY Trial by year-end- LEXINGTON, Mass.--(BUSINESS WIRE)--May. 3, 2012-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today provided a clinical program update and reported financial results for the quarter ended March 31, 2012. “This year we made significant progress in the clinical development of ganetespib, our lead Hsp90 inhibitor, for cancer,” said Safi Bahcall,... 
Printer Friendly Version
Stock Quote
SNTA (Common)
ExchangeNASDAQ (US Dollar)
Price$4.00
Change (%) Stock is Down 0.12 (2.91%)
Volume1,406,565
Data as of 05/17/12 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
Title
Corporate Presentation
Synta Provides Clinical Update and Reports First Quarter 2012 Financial Results
Corporate Fact Sheet
2011 Annual Report to Shareholders
10-K Annual report which provides a comprehensive overview of the company for the past year
Upcoming EventsMore >>
May 2012?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-2-112345
6789101112
13141516171819
20212223242526
27282930315152
Updated 05/17/12
Most Viewed Links
1.Stock Quote
2.Quarterly Earnings
3.Historical Price Lookup
4.Online Investor Kit
5.Stock Chart
* Data collected 04/23/12 - 04/30/12

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

ABOUT |  PIPELINE |  CLINICAL TRIALS |  TECHNOLOGY |  INVESTORS  |  CAREERS

Copyright © 2009 Synta Pharmaceuticals Corp. All rights reserved.Terms of Use